Introduction In 2008, the six tumor types covered in this report are forecast to account for over 961,000 new cases of cancer. Collectively, the 32 different drugs in Phase III development for the six tumor types are forecast to achieve $4,789m in sales by 2017. This constitutes a significant proportion of the oncology market, thus representing ample commercial opportunities for drug developers.
Scope
Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types
Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions
Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types
Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs
Report
Highlights Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) and brivanib (BMS-582664; Bristol-Myers Squibb) show the most potential in the colorectal cancer pipeline. Aflibercept has shown activity following failure of prior standard Avastin (bevacizumab; Genentech/Roche), while brivanib's novel mechanism of action could represent a first-in-class therapy.
Melanoma is the most popular R&D target of the six tumor types covered in this report, due to persistent high unmet needs and a substantial incidence. Elesclomol (STA-4783; Synta Pharmaceuticals/GlaxoSmithKline) currently shows the most potential at present, although only if successful Phase II results can be replicated in Phase III studies.
First-line axitinib (AG-13736; Pfizer) and Gemzar (gemcitabine; Eli Lilly) showed similar response rates and overall survival to first-line Gemzar and Tarceva (erlotinib; Genentech/Roche) in pancreatic cancer. If this can be replicated in Phase III trials, approval is likely, given that Tarceva was approved based on a 2-week survival benefit.
Reasons
to Purchase
Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment
Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to fulfil them
Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products
Table
of Contents
Please click on the link below to view further information on this product (a new window
will open):
If you require further
information on this product or would like to purchase by invoice call our customer service
number:
(+1) 800-759-0261 or Email
us.
If you require assistance please Email
us or call +1-800-759-0261.
